Product
TransCon CNP
Aliases
Placebo for TransCon CNP
4 clinical trials
1 indication
Indication
AchondroplasiaClinical trial
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2022-09-27
Clinical trial
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With AchondroplasiaStatus: , Estimated PCD: 2039-01-01
Clinical trial
ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With AchondroplasiaStatus: Active (not recruiting), Estimated PCD: 2023-03-15